Back

Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study

28 August 2017 (08:30 - 08:45)
Organised by:
Congress Presentation Part of: Late-Breaking Science in Heart Failure Heart failure, other ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Anna Norhammar

Karolinska Institute, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail
Efficacy of beta-blockers in heart failure according to left ventricular ejection fraction: An individual patient level analysis of double-blind randomised trials
Professor D. Kotecha (Birmingham, GB)
Slides Video
Presentation thumbnail
Marked variation in the efficacy of beta-blockers across cardiovascular health: A Global systematic assessment of mortality, myocardial infarction and stroke
Doctor O. Ziff (Birmingham, GB)
Slides Video
Presentation thumbnail
Heart Failure-Wii study
Professor T. Jaarsma (Linkoping, SE)
Slides Video
Presentation thumbnail
Does the risk for heart failure (HF) modulate the effectiveness of empagliflozin on HF hospitalisation or CV death in patients with type 2 diabetes without HF? Insights from EMPA-REG OUTCOME
Professor J. Butler (Dallas, US)
Slides Video
Presentation thumbnail
Predicting right heart failure after implantation of continuous flow left ventricular assist devices (EUROMACS-RHF) score: analysis of the EUROMACS data
Professor O. Soliman (Dublin, IE)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science in Heart Failure

The Event

Event poster

ESC Congress 2017

28 August 2017 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources